On Oct 31, major Wall Street analysts update their ratings for $AtriCure (ATRC.US)$, with price targets ranging from $36 to $60.
J.P. Morgan analyst Robbie Marcus maintains with a buy rating, and adjusts the target price from $30 to $40.
UBS analyst Danielle Antalffy maintains with a buy rating, and adjusts the target price from $35 to $40.
Oppenheimer analyst Suraj Kalia maintains with a buy rating, and adjusts the target price from $32 to $36.
Needham analyst Michael Matson maintains with a buy rating, and adjusts the target price from $34 to $40.
Stifel analyst Rick Wise maintains with a buy rating, and adjusts the target price from $26 to $36.
Furthermore, according to the comprehensive report, the opinions of $AtriCure (ATRC.US)$'s main analysts recently are as follows:
AtriCure's recent quarter was described as 'exciting,' surpassing sales expectations by 3.4%, indicating a robust performance. Even considering some impact from PFA, the MIS Ablation business's underperformance is seen as not detrimental to the company's sustained mid-teens growth outlook. AtriCure continues to focus on enhancing profitability and anticipates achieving positive cash flow in FY25.
AtriCure's third-quarter revenues reached $116M, marginally surpassing the anticipated $113M and consensus estimate of $112M. Analysts maintain a tactically constructive stance on AtriCure, noting a favorable risk/reward profile with the company trading at approximately 2.7 times FY25 sales compared to its small-cap MedTech peers, which average around 3.7 times.
Here are the latest investment ratings and price targets for $AtriCure (ATRC.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月31日，多家华尔街大行更新了$AtriCure (ATRC.US)$的评级，目标价介于36美元至60美元。
摩根大通分析师Robbie Marcus维持买入评级，并将目标价从30美元上调至40美元。
瑞士银行分析师Danielle Antalffy维持买入评级，并将目标价从35美元上调至40美元。
奥本海默控股分析师Suraj Kalia维持买入评级，并将目标价从32美元上调至36美元。
Needham分析师Michael Matson维持买入评级，并将目标价从34美元上调至40美元。
斯迪富分析师Rick Wise维持买入评级，并将目标价从26美元上调至36美元。
此外，综合报道，$AtriCure (ATRC.US)$近期主要分析师观点如下：
AtriCure最近的一个季度被描述为“令人振奋”，销售额超过预期3.4%，显示出强劲的业绩。即使考虑到一些来自PFA的影响，MIS Ablation业务的表现不佳被认为对公司持续的中等年增长预期不具有破坏性。AtriCure继续专注于增强盈利能力，并期待在FY25实现正现金流。
AtriCure的第三季度营收达到11600万美元，略超过预期的11300万美元和共识预期的11200万美元。分析师对AtriCure保持战略性的建设性立场，指出公司以约2.7倍FY25营收进行交易，而其小型医疗技术同行平均约为3.7倍，显示出有利的风险/回报比。
以下为今日6位分析师对$AtriCure (ATRC.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
